adipocyte mitochondrial genes and the forkhead factor foxc2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone脂肪细胞的线粒体基因和foxc2 forkhead因素减少2型糖尿病患者和规范化对罗格列酮的反应.pdfVIP

Håkansson et al. Diabetology Metabolic Syndrome 2011, 3:32 DIABETOLOGY /content/3/1/32 METABOLIC SYNDROME RESEARCH Open Access Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone 1,2* 3 3 1 Joakim Håkansson , Björn Eliasson , Ulf Smith and Sven Enerbäck Abstract Background: FOXC2 has lately been implicated in diabetes and obesity as well as mitochondrial function and biogenesis and also as a regulator of mtTFA/Tfam. In this study, the expression of FOXC2 and selected genes involved in mitochondrial function and biogenesis in healthy subjects and in a matched cohort with type 2 diabetes patients before and after treatment with rosiglitazone was determined. Quantitative real time PCR was used to analyze both RNA and DNA from biopsies from subcutaneous adipose tissue. Methods: Blood samples and subcutaneous abdominal fat biopsies were collected from 12 T2D patients, of which 11 concluded the study, pre-treatment and 90 days after initiation of rosiglitazone treatment, and from 19 healthy control subjects on the first and only visit from healthy subjects. Clinical parameters were measured on the blood samples. RNA and DNA were prepared from the fat biopsies and gene expression was measured with real time PCR. Results: The expression level of genes in the mitochondrial respiratory complexes I - IV were significantly downregulated in the diabetic patients and restored in response to rosiglitazone treatment. Rosiglitazone treatme